Share Capital is a venture capital firm specializing in seed, start-up, early, middle, growth capital, and Pre-IPO investments. it primarily invests in big living, medical healthcare, and internet innovation. In medical healthcare, it seeks to invests in pharmaceuticals, innovative equipment, biotechnology, diagnostic testing equipment and reagents, anti-infectives, drug discovery, medical health service, mobile medical services, and informatization.

Share Capital

Guangzhou Yuexiu Industrial Investment Fund is a corporate investment arm of Yue Xiu Enterprises (Holdings) Limited.

Guangzhou Yuexiu Industrial Investment Fund

Sangel Capital as one of the earliest globally operating professional biomedical venture capital institutions was established in China in 2010, focusing on life science and technology, and having leading professional advantages and rich project resources in the biomedical investment industry.  Sangel Capital has offices in Shenzhen, Beijing, Suzhou, and Chicago. We bring together a group of investment and advisory teams composed of industry experts, scientists, and investors in the field of life technology to manage and operate a series of RMB and USD funds.

Sangel Capital

Zheshang Industrial Integration Asset Management is an investment firm.

Zheshang Industrial Integration Asset Management

Jiuyou Capital has strong background resources in the fields of private equity investment institutions, public funds, wealth companies, banks, trusts, investment banks and brokerages. Relying on the shared economy model of “Internet + Social + Finance”, Jiuyou Capital is committed to building a more optimized and efficient investment industry ecosystem, and thus becomes China's most influential financial resource integration and service platform.

Jiuyou Capital

Zhejiang Xianju Pharmaceutical Co., Ltd (仙琚制药) is a Chinese company manufacturing steroid drug products, steroid hormone medicines, and medicines for birth control.  The company’s main business is focused on the development, production, and sale of raw materials and preparation of pharmaceutics for steroid drugs. Its products are based on three categories: corticosteroid drugs, sex hormone drugs (gynecological and birth control medication), and anesthesia and muscle relaxation drugs. These categories consist of more than 200 varieties of drugs.  Currently, all the products of the company have passed the authentication of GMP. It has built a long-term partnership with more than twenty famous scientific research institutes and universities in China such as Shanghai Institute of Organic Chemistry and Chinese Pharmaceutical University.  Xianju Pharmaceutical was established in 1972.

Zhejiang Xianju Pharmaceutical

GoldStone Investment Ltd. (GoldStone Investment) was incorporated in Beijing in October 2007 with a registered capital of RMB 4.6 billion. As a wholly-owned subsidiary of CITIC Securities, it is solely engaged in direct equity investment and focuses on the private companies with the potential of going public. In pursuant to the approval by CSRC, GoldStone Investment was among the first to conduct the pilot operation of direct equity investment. GoldStone Investment completed a total investment of over RMB 3.84 billion in 2010; 56 investment deals were closed in the year, including 7 deals with successful IPO. The Beijing Agricultural Industry Investment Fund managed by GoldStone Investment achieved remarkable progress in 2010 by completing an investment of RMB 200 million, which accounted for 20% of the total size of the fund. A new proceeds of RMB 2 million was also raised in the year. In 2010, GoldStone Investment was granted the award of ¡°Investment Institution Excellence¡± which was jointly sponsored by Shanghai Securities News and elected by a number of financial institutions and media.

GoldStone Investment

Established in 1995 as the first joint venture investment bank in China, China International Capital Corporation Limited (CICC) is a leader in providing comprehensive financial services including investment banking, capital markets, institutional and individual securities sales and trading, fixed income, asset management, private equity, individual wealth management and research.

CICC

Yingke Capital is a principal investment firm specializing in pre-IPO investments. It seeks to invest in 5G internet of things, biomedical, environmental and facilities services, new energy, consumer upgrade, smart manufacturing and materials sector.  Yingke Capital prefers to invest in companies with high technology R&D and production capacity. Mingfei Qian founded it in 2010, with its headquarters in Fuzhou in China.

Yingke Capital

CICC Qide is an investment management firm.

CICC Qide

Fang Fund is an equity investment fund and focuses on new economic fields, with a particular focus on big data, new media, intelligent technology (AR/VR), alternative energy resources, new materials and health care.   Fang Fund Partners management team has years of successful business practices and venture investment experience. The team is committed to providing value-added services for invested companies, grafting quality social resources and aligning with the ecological industry chain.  Fang Fund Partners  vision is to become a fund that understands entrepreneurs best and helps them fulfill their dreams, in an effort to promote social progress and contribute to the welfare of human beings.  Fang Fund Partners have unique insight into startup experience of honorable entrepreneurs.   Fang Fund Partners Advantages  A wide range of project sources： ν	Over 30,000 quality project sources each year ν	Parallel investment in Greater China, United States (East and West Coast), Israel and Europe  Abundant industrial resources ν	Fund’s partners include well-known entrepreneurs and industrial leaders ν	Fund’s management team has rich practical experience and industrial resources  Solid value-adding services ν	Fang Fund Partners can support the invested companies in various aspects, such as capital, big data, human resources, marketing & sales strategy and industry cooperation ν	Fang Fund Partners can bring a broader international perspective and comprehensive strategic plans to our invested companies

Fang Fund Partners

Zhejiang Silicon Paradise Asset Management Group (“TTGG” or “Company”) was founded on Nov. 11, 2000. It has become one of the largest private equity companies in China, No. 1 in Zhejiang Province. Currently, the Company has registered capital of RMB1.2bn, and its shareholders include Heaven-Sent Capital Management Group, Qianjiang Water Resources Development Co., Ltd., Zhejiang Orient Holdings Co., Ltd., Minfeng Special Paper Co., Ltd., Chint Group, and Zhejiang Research Institute of Chemical Industry.

Zhejiang Paradise

China Resources Pharmaceutical Group operates as a pharmaceutical company. The Company researches, develops, manufactures, and distributes Chinese, western, and other medicines and health foods. China Resources Pharmaceutical serves customers throughout China.

China Resources Pharmaceutical Group

HosenCare Brothers is a venture capital firm.

HosenCare Brothers

Denovo Biopharma

Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stage clinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology.

Denovo Biopharma LLC is a clinical-stage biopharmaceutical company that utilizes a novel biomarker approach to execute efficient, patient-targeted clinical trials for innovative therapies. The company has eight late-stage drug candidates in its pipeline, the majority of which are first-in-class drugs with global rights, addressing major unmet medical needs in oncology and central nervous system (CNS) diseases.

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Honeywell Technology To Power DevPro Biopharma’s Next-generation Low-Emission Respiratory Inhaler .. honeywell;devpro biopharma . partner

Qiagen

To develop a blood-based companion diagnostic (CDx) test to identify patients expressing Denovo Genomic Marker 1 (DGM1TM) who are likely to respond to Denovo’s investigational cancer drug DB102TM for treatment of diffuse large B-cell lymphoma (DLBCL).

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Denovo Biopharma LLC is a clinical-stage biopharmaceutical company that utilizes a novel biomarker approach to execute efficient, patient-targeted clinical trials for innovative therapies. The company has eight late-stage drug candidates in its pipeline, the majority of which are first-in-class drugs with global rights, addressing major unmet medical needs in oncology and central nervous system (CNS) diseases.Denovo's key product offerings include DB104 (liafensine), a first-in-class triple reuptake inhibitor targeting transporters for dopamine, serotonin, and norepinephrine. In April 2024, the company announced positive results from the ENLIGHTEN Phase 2 billion clinical trial, which assessed the efficacy and safety of DB104 in patients with treatment-resistant depression (TRD). The trial met all major study endpoints, demonstrating highly significant improvements in depression symptoms compared to placebo, with over 40% improvement observed.Another promising candidate is DB107, a late-stage gene therapy for high-grade glioma and glioblastoma, acquired from Tocagen in 2020. The company also has ongoing biomarker-guided Phase three trials for its lead asset DB102 (enzastaurin) in diffuse large B-cell lymphoma and glioblastoma. As of January 2022, over 1,700 subjects have been treated with DB104 across multiple clinical trials.Denovo's approach involves identifying novel biomarkers that can predict a patient's response to its drug candidates, enabling precision medicine and optimizing trial success rates. For instance, the DGM4 biomarker was discovered to predict liafensine's efficacy in TRD patients, leading to the biomarker-guided ENLIGHTEN study. Key customers and partnershipsIn July 2022, Denovo entered into a Master Services Agreement with Nurosene Health Inc., a healthtech company focused on AI-based technology solutions for mental performance and wellness. Under this agreement, Nurosene's NetraMark division will aid in determining factors driving drug response and placebo response in Denovo's TRD clinical trials, leveraging its proprietary NetraAI technology.

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

PROMINENT_CATEGORY

<div>
 
 Denovo Biopharma, a clinical-stage biopharmaceutical company, has recently disclosed positive results from its phase 2b clinical trial, ENLIGHTEN. The said trial involves DB104 or Liafensine, a triple reuptake inhibitor designed to target and transport serotonin, norepinephrine, and dopamine. Its major objective is to address treatment-resistant depression (TRD).
 A pivotal part of this trial is the employment of the Big Data-based Denovo Genomic Marker (DGM), particularly DGM4, a groundbreaking genetic biomarker. This is used to anticipate the therapeutic effect of Liafensine on patients. According to Denovo, the application of DGM4 in choosing patients for the trial brought about a significant elevation in both primary and secondary outcomes in TRD patients. It showed over 40% amelioration in symptoms of depression.
 Denovo Biopharma concentrates on developing biomarker-driven precision medicines. Its unique platform, the Denovo Genomic Database (DGB), aids in identifying biomarkers that foretell patient responses to certain drugs. Consequently, this enables the company to develop new medications that are custom-made to patients' genetic characteristics. Some of the drugs in Denovo's therapeutic portfolio include DB102 (enzastaurin) intended for glioblastoma, DB104 (liafensine) for treatment-resistant depression, and DB107, an anti-cancer gene therapy-based drug.
 
</div>

Denovo Biopharma

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless